New Direct-to-Tumor injections tested for Tough-to-Treat cancers

NCT ID NCT07382531

Recruiting now Disease control Sponsor: Binhui Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This early-stage trial is testing the safety and effectiveness of two experimental drugs, OH2 and BS006, injected directly into tumors. It is for adults with advanced solid cancers (like melanoma, liver, or pancreatic cancer) who have already tried and failed standard treatments. The main goal is to see if the combination is safe and tolerable, while also checking if it can shrink tumors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Zhongnan Hospital of Wuhan University
RECRUITING

Wuhan, Hubei, 430000, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR